WallStSmart

Catalyst Pharmaceuticals Inc (CPRX)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Catalyst Pharmaceuticals Inc generates 79279% more annual revenue ($588.99M vs $742,000). CPRX leads profitability with a 36.4% profit margin vs 0.0%. CPRX earns a higher WallStSmart Score of 57/100 (C).

CPRX

Buy

57

out of 100

Grade: C

Growth: 6.0Profit: 10.0Value: 5.3Quality: 8.5
Piotroski: 2/9Altman Z: 6.50

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 7.3
Piotroski: 2/9Altman Z: 3.27

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CPRX5 strengths · Avg: 9.8/10
Profit MarginProfitability
36.4%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
40.5%10/10

Strong operational efficiency at 40.5%

Debt/EquityHealth
0.0010/10

Conservative balance sheet, low leverage

Altman Z-ScoreHealth
6.5010/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.5%9/10

Every $100 of equity generates 26 in profit

RVMD1 strengths · Avg: 10.0/10
Altman Z-ScoreHealth
3.2710/10

Safe zone — low bankruptcy risk

Areas to Watch

CPRX2 concerns · Avg: 2.5/10
Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-6.4%2/10

Earnings declined 6.4%

RVMD4 concerns · Avg: 3.5/10
Price/BookValuation
17.1x4/10

Trading at 17.1x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : CPRX

The strongest argument for CPRX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 36.4% and operating margin at 40.5%.

Bull Case : RVMD

The strongest argument for RVMD centers on Altman Z-Score.

Bear Case : CPRX

The primary concerns for CPRX are Piotroski F-Score, EPS Growth.

Bear Case : RVMD

The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.

Key Dynamics to Monitor

CPRX profiles as a mature stock while RVMD is a value play — different risk/reward profiles.

RVMD carries more volatility with a beta of 1.41 — expect wider price swings.

CPRX is growing revenue faster at 7.6% — sustainability is the question.

CPRX generates stronger free cash flow (45M), providing more financial flexibility.

Bottom Line

CPRX scores higher overall (57/100 vs 24/100), backed by strong 36.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Catalyst Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, neuromuscular, and chronic neurological diseases in the United States. The company is headquartered in Coral Gables, Florida.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?